PubMed · 5416407
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
C Bosanquet. 1970. Getting in touch.. https://doi.org/10.1111/j.1465-5922.1970.00042.x
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
This article reviews the process of public response to warnings of an impending nuclear power plant emergency. Significant evidence exists to suggest that people engage in protective action in response to warnings based upon the substance and course through which emergency warning information is disseminated. The three basic components of a warning system are defined, and the elements of public response to warnings are summarized. Popular myths about public response to warnings are outlined and dispelled based upon current research verification. The conclusion provides an overview and synthesis of the warning response process.
Physicians increasingly are called on to provide primary care for the growing population of people with Alzheimer-type dementia. However, little attention has been paid to the care of nondementia illnesses in this group of patients. To illustrate how presence of dementia can alter the risk-benefit ratio of treatment of a common medical problem, we present a case study in which a patient with dementia developed disastrous adverse effects to a drug commonly used to treat osteoporosis. This case and 2 composite vignettes illuminate how presence of dementia should influence the decision-making process for treatment of nondementia illnesses. We address issues such as decreased decision-making capacity, problems with reporting adverse effects, decreased cognition leading to problems with treatment adherence, and the role of screening and basic questions about acceptable burdens of treatments in patients with limited prognosis. We suggest ways to improve communication with patients with dementia in an effort to minimize complications and improve care, as well as policy changes to include patients with dementia in clinical trials. JAMA. 2000;283:3230-3235
Explore the source record for details and available documents.